Second Failure Knocks Argenx’s Vyvgart Blockbuster Expansion Plans

A Phase III study may have been scuppered by its design, but Argenx remains confident that Vyvgart will still be an autoimmune disease 'pipeline in a product'.

Argenx’s expansion plans for its blockbuster-in-the-making, Vyvgart, have been dealt a blow by a Phase III failure.

The subcutaneous version of its drug, Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), failed to help patients with two forms of a chronic autoimmune blistering condition

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.